Consensus on Clinical Management of Tumor-Induced Osteomalacia

0
0
0

Consensus on Clinical Management of Tumor-Induced Osteomalacia

If you’ve ever struggled with unexplained bone pain, muscle weakness, or fractures that won’t heal, you might have encountered osteomalacia—a condition where bones soften due to low phosphate or vitamin D. But for some people, the root cause is more unexpected: tumor-induced osteomalacia (TIO), a rare paraneoplastic syndrome where small tumors overproduce fibroblast growth factor 23 (FGF23). This hormone drains phosphate from the blood, wreaking havoc on bone health. For years, TIO was misdiagnosed or missed entirely—until a 2021 consensus from global experts aimed to fix that.

The guidelines, led by Yan Jiang, Xiang Li, and a team of specialists from China’s top medical institutions (including Peking Union Medical College Hospital, the Chinese PLA General Hospital) and Italy’s Sapienza University of Rome, were published in the Chinese Medical Journal. They offer clear, practical steps to diagnose and treat TIO—filling a critical gap for doctors and patients worldwide.

What Is TIO, and How Do You Diagnose It?

TIO happens when tumors (usually small, slow-growing, and hard to find) make too much FGF23. This throws off the body’s phosphate balance: low phosphate weakens bones, causing pain, fractures, or “Looser zones”—pseudofractures visible on X-rays.

To diagnose TIO, doctors use three pillars:

  1. Clinical symptoms: Bone pain, muscle weakness, mobility issues, or signs of osteomalacia on imaging.
  2. Blood tests: Low serum phosphate, low or normal 1,25-dihydroxyvitamin D (the active form of vitamin D), high alkaline phosphatase (ALP, a marker of bone damage), and elevated FGF23.
  3. Rule out other causes: First, exclude inherited disorders (like X-linked hypophosphatemic rickets) or acquired conditions that cause low phosphate.

Once TIO is suspected, the hunt for the tumor begins. TIO tumors can grow anywhere—from the hands to the sinuses—so experts recommend a stepwise approach:

  • Functional imaging first: Use 68Ga-DOTA-conjugated somatostatin receptor PET/CT or octreoscan (single-photon emission CT). These scans light up tumors that take up somatostatin, a hormone many TIO tumors rely on.
  • Anatomical imaging to confirm: If a spot is found, use MRI or CT (high-resolution tools) to verify the tumor’s location and size.
  • Repeat if no tumor is found: If scans come up empty, start treatment and repeat imaging in 1–2 years.

The Tumor Behind TIO: Phosphaturic Mesenchymal Tumors

Nearly all TIO-causing tumors are phosphaturic mesenchymal tumors (PMTs)—soft tissue or bone growths from mesenchymal (connective) tissue. Even though PMTs look different under a microscope, they share a unique signature: a “smudgy” matrix (tissue structure) that calcifies in a clumpy, “grungy” way. This helps pathologists confirm the diagnosis.

How to Treat TIO

The goal of treatment is simple: stop FGF23 overproduction, restore phosphate levels, and heal bones. Here’s what experts recommend:

1. Surgery (First-Line if Possible)

Complete tumor removal is the cure. In most cases, this fixes biochemical abnormalities (like low phosphate) within days and lets bones remineralize. But even a tiny piece of tumor left behind can cause a relapse—so doctors stress complete excision. If symptoms return or don’t improve, repeat the diagnostic workup to find any remaining tumor.

2. Medical Therapy (For Inoperable Tumors)

If surgery isn’t an option, drugs can manage symptoms:

  • Burosumab: A monoclonal antibody that blocks FGF23. The initial dose is 0.5 mg/kg every 4 weeks, adjusted based on phosphate levels.
  • Phosphate + active vitamin D: For those without access to burosumab, take 1–3 grams of elemental phosphate daily (split into 4–6 doses) plus calcitriol (0.5–1.5 mg daily) or alphacalcidol (1.5–2x the calcitriol dose). The goal is to ease pain, raise phosphate, and keep parathyroid hormone (PTH) normal—not to fully normalize phosphate (that can cause side effects).

3. Monitoring

  • After surgery: Check serum phosphate every 6 months (then yearly) and get a DXA scan (bone density test) regularly.
  • Long-term medical therapy: Check blood work (phosphate, calcium, ALP, PTH, renal function) every 3–6 months to adjust doses and prevent side effects (like kidney stones or high PTH).

What’s Next for TIO?

Experts want to make TIO easier to diagnose in primary care—with simple, accessible criteria. They also aim to:

  • Unlock the mystery of why tumors make too much FGF23.
  • Develop tools to predict TIO severity or resistance to treatment.
  • Test new drugs (like FGFR1 inhibitors) to expand options for hard-to-treat cases.

This consensus was published in the Chinese Medical Journal in 2021 by Yan Jiang, Xiang Li, Wei-Bo Xia, Salvatore Minisola, and colleagues from the Chinese Society of Osteoporosis and Bone Mineral Research and Chinese Society of Endocrinology.

doi.org/10.1097/CM9.0000000000001448

Was this helpful?

0 / 0